New combo therapy targets breast cancer brain metastases in early trial
NCT ID NCT03807765
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-phase study tested whether combining stereotactic radiosurgery (precise radiation) with the immunotherapy drug nivolumab (Opdivo) is safe and can shrink tumors in people with breast cancer that has spread to the brain. Fourteen participants received the combination. The main goal was to check for serious neurological side effects, not to prove the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab (Opdivo) and stereotactic radiosurgery
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for breast cancer that has spread to the brain.
What could go wrong
This is a very early phase 1 trial with only 14 participants, focused on safety. It is not designed to prove the treatment works, and there are risks of serious neurological side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.